UK Government Advises on Chemical Use if No-Deal Brexit Occurs

| January 28, 2019

article image
The UK government has issued guidance to businesses that use chemicals on the actions they should take now to minimize any disruption in the event of a no-deal Brexit. If the UK leaves the EU on March 29 without a deal, UK businesses that manufacture or import chemicals from the EU will reportedly have to register those chemicals to a new UK regulatory system. UK Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) will replace EU REACH and will require businesses to demonstrate how a chemical can be safely used with minimal risk to human health or the environment.

Spotlight

New Haven Pharmaceuticals, Inc.

New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs. By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.

OTHER ARTICLES
CHEMICAL MANAGEMENT

Southeast polyolefins demand growth could be negative again in 2021

Article | July 13, 2021

BEFORE the pandemic, GDP growth rates in the developing world were always higher than in developed economies.And because developing economies had much lower levels of petrochemicals consumption than their rich counterparts, it meant that the multiples over GDP were higher than in the rich word, where consumption was pretty much saturated. For instance, polyethylene (PE) demand in a developed country such as Germany might have grown at 0.3% times GDP whereas in Indonesia the growth could have been one or more times higher than the rate of growth in GDP.But as The Economist wrote in this 11 July article: “In 2021 the poorest countries, which are desperately short of vaccines, are forecast to grow more slowly than rich countries for only the third time in 25 years.” Might the multiples over GDP growth also be adversely affected in the developing world, trending lower than the historic norms? They will almost certainly remain higher than the rich countries. But here is the thing: as millions more people are pushed back into extreme poverty by the pandemic or are denied the opportunity to achieve middle-income status, I believe that developing-world multiples may well decline.Escaping extreme poverty means being able to, say, afford a whole bottle of shampoo for the first time rather than a single-serve sachet, thereby raising per capita polymers consumption.

Read More
CHEMICAL MANAGEMENT

Pandemic’s third wave seems unlikely to damage global petrochemicals demand

Article | July 22, 2021

Petrochemical stocks plunged worldwide on 19 July ahead of the Q2 earnings season. The declines were consistent with those in economically sensitive sectors such as steel, copper, automotive and housing,” wrote my ICIS colleague, Joseph Chang, in this Insight article.

Read More
CHEMICAL TECHNOLOGY

Reimagining the Workforce with Anglo American

Article | June 21, 2021

“At Anglo-American, we’re really focused on finding the best ways to attract the most talented people in the industry and effectively equipping our existing workforce based on what they need today and what the future will mean for their careers. We’re also committed to providing learning opportunities that lead to growth and development in the communities in which we operate. Our people are a strategic advantage. We want to ensure that continues to be the case as the mining industry evolves and faces more disruption.

Read More
CHEMICAL MANAGEMENT

Energy portfolio restructuring: Charting the future

Article | June 17, 2021

Consumer needs and preferences in the energy industry are evolving. Environmental, social and governance (ESG) concerns are becoming more acute—inspiring action and shifting value towards low-carbon solutions. These trends accelerated in 2020 and for the first time, market capitalization of leading low-carbon solutions companies began to overtake those of oil and gas (O&G) majors. This is despite the majors laying out energy transition strategies, setting low carbon energy targets and generating higher revenues by an order of magnitude.1 In response to this radically changing landscape, energy companies are charting divergent courses for their futures. Some continue to bet on their ability to generate returns from the O&G value chain. They are focusing on growing margins and lowering carbon intensity. Others are supplementing their capabilities with low-carbon energy solutions or exiting hydrocarbons altogether. This blog focuses on the path forward for the energy majors in Europe who are betting big on diversification.

Read More

Spotlight

New Haven Pharmaceuticals, Inc.

New Haven Pharmaceuticals unites industry-leading experience with data-driven insight. By applying contemporary metadata analysis to large volumes of medical information, New Haven Pharmaceuticals is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs. By combining this evolutionary approach to drug development with its state-of-the-art technology platforms, the Company creates economies of scale and rapid development processes that are highly valued in today's managed care environment. These efficiencies will become increasingly important as Accountable Care Organizations (ACOs) help physicians, hospitals and patients move away from a volume-based reimbursement system and toward a value-based system focused on meeting appropriate medical goals for each patient.

Events